Stephens initiated coverage on Hologic Inc HOLX, citing it as a major player in women's health, known for its consistent revenue growth, strong free cash flow, and attractive profit margins, is well-positioned in the molecular diagnostics sector post-COVID. Stephens analyst writes, "Hologic is a leader in women's health with a portfolio of products that have become the gold standard for care. Hologic emerged from the pandemic with new growth drivers, a scaled installed base, and a stronger balance sheet." T ...

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Investors interested in stocks from the Medical - Instruments sector have probably already heard of Hologic (HOLX) and Edwards Lifesciences (EW) . But which of these two sto ...

The most recent trading session ended with Hologic (HOLX) standing at $71.65, reflecting a -1.15% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily gain of 0.09%. At the same time, the Dow lost 0.1%, and the tech-heavy Nasdaq gained 0.16%. The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is forecasted to report an EPS of $1.02, showcasing a 9.68% upward movement from the corr ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sellside) analysts often affect a stock's price, do they really matter? Hologic currently has an average brokerage recommendation (ABR) of 2.00, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 14 brokerage firms. An ABR of 2. ...

Hologic has a Zacks Rank of #2 (Buy), while Edwards Lifesciences has a Zacks Rank of #3 (Hold) right now. This means that HOLX's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in. HOLX currently has a forward P/E ratio of 18.26, while EW has a forward P/E of 31.82. We also note that HOLX has a PEG ratio of 2.48. This metric is used similarly to the famous P/ ...

As quoted in a Markets Insider report, the strategist warns that investors' optimism has driven the market to record highs following the U.S. Federal Reserve's recent policy update confirming the rate cut expectations in 2024. In contrast to the investor sentiment, Hussman maintains a bearish outlook, warning of a potential downturn. Citing the dramatic escalation of debt levels since the 2008 crisis, expert Jim Rogers has also voiced concerns about the possibility of a very big correction in the coming mon ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell- side) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Hologic (HOLX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Hologic currently has an average brokera ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Hologic (HOLX) .Hologic currently has an average brokerage recomm ...

The Good Brigade In February, I believed that shares of Hologic, Inc. (NASDAQ:HOLX) were starting to look a bit more attractive as headwinds were disappearing. The women's health business benefited greatly from the pandemic (through its diagnostics business) yet the subsequent headwinds are ending in 2024. This improves the prospects for growth as appeal was slowly emerging, with year-over-year growth appearing in the coming quarters. All this looks quite compelling amidst a strong balance sheet, solid trac ...

Did you analyze how Hologic (HOLX) fared in its international operations for the quarter ending March 2024? Given the widespread global presence of this medical device maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential fo ...